Literature DB >> 19405126

Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma.

Mauting Lin1, Carl D Morrison, Susie Jones, Nehad Mohamed, Jason Bacher, Christoph Plass.   

Abstract

Gene amplification, a common mechanism for oncogene activation in cancers, has been used in the discovery of novel oncogenes. Low-level copy number gains are frequently observed in head and neck squamous cell carcinomas (HNSCCs) where numerous amplification events and potential oncogenes have already been reported. Recently, we applied restriction landmark genome scanning to study gene amplifications in HNSCC and located novel and uncharacterized regions in primary tumor samples. Gain on chromosome 8q22.3, the location of YWHAZ (14-3-3zeta), is found in 30-40% HNSCC cases. Data obtained from fluorescence in situ hybridization and immunohistochemistry on HNSCC tissue microarrays confirmed frequent low-level YWHAZ copy number gain and protein overexpression. YWHAZ mRNA was frequently upregulated in patients' tumor tissues. Furthermore, YWHAZ RNAi significantly suppressed the growth rate of HNSCC cell lines, and overexpression of YWHAZ in HaCaT immortalized human skin keratinocytes promotes overgrowth, as well as morphological changes. Reduced YWHAZ levels increased the G1/G0-phase proportion, decreased the S-phase proportion and the rate of DNA synthesis. Based on this evidence, we suggest that YWHAZ is a candidate proto-oncogene and deserves further investigation into its role in HNSCC carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19405126      PMCID: PMC2756013          DOI: 10.1002/ijc.24346

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  61 in total

1.  MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome.

Authors:  Carl Morrison; Michael Radmacher; Nehad Mohammed; David Suster; Herbert Auer; Susie Jones; Judy Riggenbach; Nicole Kelbick; Gary Bos; Joel Mayerson
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Genetic aberrations in prostate cancer by microarray analysis.

Authors:  Outi R Saramäki; Kati P Porkka; Robert L Vessella; Tapio Visakorpi
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

Review 3.  The role of overexpressed HER2 in transformation.

Authors:  R M Neve; H A Lane; N E Hynes
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

4.  The differential proteome profile of stomach cancer: identification of the biomarker candidates.

Authors:  Joung S Jang; Hee Y Cho; Young J Lee; Woo S Ha; Hwal W Kim
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

5.  14-3-3 sigma positively regulates p53 and suppresses tumor growth.

Authors:  Heng-Yin Yang; Yu-Ye Wen; Chih-Hsin Chen; Guillermina Lozano; Mong-Hong Lee
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

6.  Constitutive overexpression of human telomerase reverse transcriptase but not c-myc blocks terminal differentiation in human HaCaT skin keratinocytes.

Authors:  Ana Cerezo; Hans-Jürgen Stark; Sharareh Moshir; Petra Boukamp
Journal:  J Invest Dermatol       Date:  2003-07       Impact factor: 8.551

7.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Authors:  Claudia D Baldus; Stephan M Tanner; Amy S Ruppert; Susan P Whitman; Kellie J Archer; Guido Marcucci; Michael A Caligiuri; Andrew J Carroll; James W Vardiman; Bayard L Powell; Steven L Allen; Joseph O Moore; Richard A Larson; Jonathan E Kolitz; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

8.  Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry.

Authors:  Ranju Ralhan; Leroi V Desouza; Ajay Matta; Satyendra Chandra Tripathi; Shaun Ghanny; Siddartha Datta Gupta; Sudhir Bahadur; K W Michael Siu
Journal:  Mol Cell Proteomics       Date:  2008-03-13       Impact factor: 5.911

9.  Bcr and Raf form a complex in vivo via 14-3-3 proteins.

Authors:  S Braselmann; F McCormick
Journal:  EMBO J       Date:  1995-10-02       Impact factor: 11.598

10.  Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.

Authors:  Markus Heidenblad; David Lindgren; Tord Jonson; Fredrik Liedberg; Srinivas Veerla; Gunilla Chebil; Sigurdur Gudjonsson; Ake Borg; Wiking Månsson; Mattias Höglund
Journal:  BMC Med Genomics       Date:  2008-01-31       Impact factor: 3.063

View more
  35 in total

1.  Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.

Authors:  Chi Zhang; Li-Xin Liu; Zhao-Ru Dong; Guo-Ming Shi; Jia-Bin Cai; Peng-Fei Zhang; Ai-Wu Ke; Jing-Xian Yu; Jian Zhou; Jia Fan
Journal:  Tumour Biol       Date:  2014-11-13

2.  Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis.

Authors:  Aditi Bhattacharya; Ritu Roy; Antoine M Snijders; Gregory Hamilton; Jesse Paquette; Taku Tokuyasu; Henrik Bengtsson; Richard C K Jordan; Adam B Olshen; Daniel Pinkel; Brian L Schmidt; Donna G Albertson
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 3.  14-3-3 proteins as potential therapeutic targets.

Authors:  Jing Zhao; Cheryl L Meyerkord; Yuhong Du; Fadlo R Khuri; Haian Fu
Journal:  Semin Cell Dev Biol       Date:  2011-10-01       Impact factor: 7.727

Review 4.  14-3-3ζ as a prognostic marker and therapeutic target for cancer.

Authors:  Christopher L Neal; Dihua Yu
Journal:  Expert Opin Ther Targets       Date:  2010-12       Impact factor: 6.902

5.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Authors:  Manoj Kumar Kashyap; H C Harsha; Santosh Renuse; Harsh Pawar; Nandini A Sahasrabuddhe; Min-Sik Kim; Arivusudar Marimuthu; Shivakumar Keerthikumar; Babylakshmi Muthusamy; Kumaran Kandasamy; Yashwanth Subbannayya; Thottethodi Subrahmanya Keshava Prasad; Riaz Mahmood; Raghothama Chaerkady; Stephen J Meltzer; Rekha V Kumar; Anil K Rustgi; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

Review 6.  14-3-3 proteins: an important regulator of autophagy in diseases.

Authors:  Haoyuan Jia; Zhaofeng Liang; Xu Zhang; Juanjuan Wang; Wenrong Xu; Hui Qian
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

7.  A time-resolved fluorescence resonance energy transfer assay for high-throughput screening of 14-3-3 protein-protein interaction inhibitors.

Authors:  Yuhong Du; Robert W Fu; Bin Lou; Jing Zhao; Min Qui; Fadlo R Khuri; Haian Fu
Journal:  Assay Drug Dev Technol       Date:  2013-08-01       Impact factor: 1.738

8.  14-3-3ζ regulates immune response through Stat3 signaling in oral squamous cell carcinoma.

Authors:  Xinguang Han; Yongfu Han; Huifeng Jiao; Yaqiong Jie
Journal:  Mol Cells       Date:  2014-12-30       Impact factor: 5.034

9.  Introducing Potential Key Proteins and Pathways in Human Laryngeal Cancer: A System Biology Approach.

Authors:  Hassan Peyvandi; Ali Asghar Peyvandi; Akram Safaei; Mona Zamanian Azodi; Mostafa Rezaei-Tavirani
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

10.  YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.

Authors:  Yan Xu; Mariateresa Fulciniti; Mehmet K Samur; Matthew Ho; Shuhui Deng; Lanting Liu; Kenneth Wen; Tengteng Yu; Zuzana Chyra; Sanika Dereibal; Li Zhang; Yao Yao; Chandraditya Chakraborty; Eugenio Morelli; Na Li; Michael A Lopez; Tommaso Perini; Shidai Mu; Gang An; Rafael Alonso; Giada Bianchi; Yu-Tzu Tai; Kenneth C Anderson; Lugui Qiu; Nikhil C Munshi
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.